Please login to the form below

European prostate cancer treatment is changing - what are the opportunities for marketers?

Consultant Jeremy Poland examines some of the key dynamics in prostate cancer multi-disciplinary teams across Europe and how the recent trends impact the opportunities available to healthcare marketers.
In this article, Consultant Jeremy Poland examines some of the key dynamics in prostate cancer multi-disciplinary teams across Europe. He will cover what we mean by multidisciplinary team, who the key stakeholders are in prostate cancer, the critical trend we are currently seeing, and the opportunities this provides to healthcare marketers operating in the area.


What is a multi-disciplinary team?

Expressed very simply, a multi-disciplinary team (MDT) represents a number of different medical functions that are involved in the management of patient care. The term MDT is itself a very British expression – across Europe the model may be referred to in a number of ways (e.g. Clinical Tumour Board, Academic Tumour Board, Multi-Specialty Practice etc.), and may be implemented with varying degrees of formality. 

In oncology, the existence of MDTs is actually nothing new. In fact, we can look back 50 years or more to the US and can find a cousin of the existing model in the form of educational tumour boards. And until relatively recently, that is exactly what they were – educational. It was the in the late 90s and early 00s when the UK, driven by public and political pressure to improve the consistency of patient care, reformed the provision of cancer services to include regular multidisciplinary meetings as a way to formally implement the MDT model. A key goal of this transformation was to improve communication between medical functions whilst also ensuring decision making was evidence based and improving continuity of care and outcomes for patients.

Such was the success of this approach in the UK, many other European countries began to follow suit and adopt the MDT model for cancer care in their region.


Key stakeholders in prostate cancer MDTs

Of course healthcare systems across the EU have their idiosyncrasies, and as such, those stakeholders involved in the management of prostate cancer (and indeed their degree of involvement) varies by region. Broadly speaking, however, the key members of an MDT will include a urologist, medical oncologist, radiation oncologist, radiologist, pathologist, pharmacist, and clinical nurse specialist – who often fulfils the role of MDT coordinator or key worker. These functions will make up the group, panel or board depending on the preference of the region. 



Download the full article from Blue Latitude Health

5th August 2016

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health
Crusader House
145-157 St John Street
London
EC1V 4QJ
United Kingdom

Latest content on this profile

How do you define a biotech company?
In the coming weeks we will be releasing a report that looks in detail at the commercial challenges and opportunities that a modern day biotech company faces. But before then, we wanted to define the playing field – what actually is a modern-day biotech company?
Blue Latitude Health
Perspective on biotech
In this supplementary issue of Perspective, we reveal the emerging technologies taking the biotech world by storm and ask if the definition of a biotech organisation needs updating.
Blue Latitude Health
Building a creative marketing consultancy: how we’ve transitioned into a full service global team
In this Q&A, James Atherton, Vice President and Managing Consultant at our New York office, reveals how our NYC and London offices work together and why having a creative services capability has changed the way we deliver strategic work for clients.
Blue Latitude Health
Creative effectiveness: how to achieve tangible results
Chris Field, Director and Head of Creative Services at Blue Latitude Health, reveals what it takes to create winning creative campaigns that achieve results in the Pharma market.
Blue Latitude Health
How to build an online medical information service that resonates with your customers
Sourcing medical information is a top challenge for healthcare professionals in 2017. Here, Blue Latitude Health Associate Consultant Jiayi Chen gives you the inside scoop on how to build a digital service that really serves the needs of your customers.
Blue Latitude Health
Could ketamine be the next big thing in depression?
Account Executive Will Frostick discusses the established treatment model for depression and its limitations, as well as a new entrant poised to revolutionise the field – ketamine.
Blue Latitude Health